Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression
Pharmaceuticals · 04.12.2024 · 17 (12) · 1627
DOI: 10.3390/ph17121627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 04.12.2024. Verfasst von Andrea Macejova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Psychiatry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Kollarova 2, 03601 Mart…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovak Scientific Grant Agency under a VEGA grant.
Themen: Depression
Abstract (Originalsprache)
Background
Adolescent treatment resistant depression (TRD) is increasing in recent years. While ketamine showed rapid antidepressant effects in adult TRD studies, research on its effectiveness in adolescents is limited.
Methods
This study examines the effects of intravenous ketamine vs. midazolam on depressive and anxiety symptomatology assessed by the Montgomery–Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), and Children’s Depression Inventory (CDI) at two time points—2 h after initial infusion (T0+2h) and 24 h after the end of the treatment (Te+24h) in a sample of 55 adolescent TRD females (27 receiving ketamine, 28 midazolam).
Results
At T0+2h, within-group comparisons revealed a significant reduction in MADRS and HAM-A scores compared to baseline in the ketamine and midazolam groups. At Te+24h, both groups demonstrated similar significant reductions in MADRS, HAM-A, and CDI scores compared to baseline. The MADRS assessment in the ketamine group showed 33% and 59% responders, and in the midazolam group, 14% and 46% responders at T0+2h and Te+24h, respectively. HAM-A evaluation in the ketamine group revealed 33% and 56% responders, and in the midazolam group, 11% and 39% responders at T0+2h and at Te+24h, respectively. CDI rating discovered 11% and 44% responders in the ketamine group and 4% and 21% responders in the midazolam group at T0+2h and Te+24h, respectively. Moreover, inner tension significantly decreased in ketamine compared to the midazolam group at Te+24h.
Conclusions
Ketamine showed a reduction in depressive and anxiety symptoms during a short-term period with particular efficacy in alleviating inner tension over midazolam, suggesting its potential advantages in specific symptom relief in rarely studied adolescent TRD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic of Psychiatry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Kollarova 2, 03601 Martin, Slovakia.
- Department of Physiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Mala Hora 4C, 03601 Martin, Slovakia.
- Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Mala Hora 4D, 03601 Martin, Slovakia.
ORCID-Profile: Ingrid Tonhajzerova, Nikola Ferencova, Zuzana Mlyncekova, Igor Ondrejka
Förderung
- Slovak Scientific Grant Agency under a VEGA grant
Zitieren
APA
Macejova, A., Kovacova, V., Tonhajzerova, I., Visnovcova, Z., Ferencova, N., Mlyncekova, Z., Kukucka, T., & Ondrejka, I. (2024). Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression. Pharmaceuticals, 17(12), 1627. https://doi.org/10.3390/ph17121627
Vancouver
Macejova A, Kovacova V, Tonhajzerova I, Visnovcova Z, Ferencova N, Mlyncekova Z, et al. Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression. Pharmaceuticals. 2024;17(12):1627. doi:10.3390/ph17121627
BibTeX
@article{Macejova2024,
author = {Macejova, Andrea and Kovacova, Veronika and Tonhajzerova, Ingrid and Visnovcova, Zuzana and Ferencova, Nikola and Mlyncekova, Zuzana and Kukucka, Tomas and Ondrejka, Igor},
title = {Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {12},
pages = {1627},
doi = {10.3390/ph17121627}
}
EUVIMED